Subscribe Sign In Register

Premium

How ValueAct Shook Off Its Big Loss from Valeant

The hedge fund firm, headed by Jeff Ubben, did not suffer the same fate as other major shareholders of the ailing pharmaceutical concern.

By Stephen Taub Stephen Taub
January 6, 2017
Valeant Pharmaceuticals Offices Ahead Of Earnings Figures

Valeant Pharmaceuticals International Inc. headquarters stands in Bridgewater Township, New Jersey, U.S., on Thursday, Aug. 4, 2016. Valeant Pharmaceuticals International Inc. is scheduled to release earnings figures on Aug. 9. Photographer: Ron Antonelli/Bloomberg

Ron Antonelli/Bloomberg

Valeant Pharmaceuticals Offices Ahead Of Earnings Figures

Valeant Pharmaceuticals International Inc. headquarters stands in Bridgewater Township, New Jersey, U.S., on Thursday, Aug. 4, 2016.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Pharmaceutical Valueact Jeff Ubben Valiant
Related
Red upward arrows with currency exchange rate
Premium
One Stock Powers a Hedge Fund to a Triple-Digit Gain
Steve Taub
November 21, 2024
Investment concept,US paper currency on Laptop and gavel,Money with a hammer.
Hedge Funds
Hound Partners Sues Tiger Management to End a Seeding Deal
Steve Taub
November 20, 2024
Person in suit works on mobile phone under money rain on grey background
Sponsored
Falling Rates Could Mean Earnings and Dividend Uncertainty